Mural Oncology (MURA) Expected to Announce Earnings on Tuesday

Mural Oncology (NASDAQ:MURAGet Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect Mural Oncology to post earnings of ($1.98) per share for the quarter.

Mural Oncology (NASDAQ:MURAGet Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the prior year, the business posted ($3.57) earnings per share. On average, analysts expect Mural Oncology to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Mural Oncology Price Performance

Shares of Mural Oncology stock opened at $4.07 on Tuesday. The stock has a market capitalization of $70.12 million, a P/E ratio of -0.45 and a beta of 3.66. The business has a 50 day simple moving average of $3.88 and a two-hundred day simple moving average of $3.60. Mural Oncology has a 12 month low of $2.87 and a 12 month high of $5.12.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a research note on Wednesday, March 12th.

View Our Latest Analysis on MURA

Mural Oncology Company Profile

(Get Free Report)

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.

Read More

Earnings History for Mural Oncology (NASDAQ:MURA)

Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.